Publication: 2037

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)
   Google Scholar   
Citation:
Blood vol 122 (21) Abstract 2882
Meeting Instance:
ASH 2013
Year:
2013
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2424  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                                       
Networks:
ESSENTIA, LAPS-MN026   
Study
NCCTG-N1087
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1/2
Keywords: